Unnamed: 0,title,date,stock,sentiment
1313819.0,"Cannabis Stock Gainers And Losers From June 10, 2020",2020-06-10 17:05:00-04:00,VIVO,negative
1313820.0,"Cannabis Stock Gainers And Losers From May 29, 2020",2020-05-30 08:59:00-04:00,VIVO,negative
1313821.0,Meridian Bioscience Announces It Will Supply Reagents For Manufacturing Of Tens Of Millions Of COVID-19 Antibody Tests Per Month,2020-05-26 08:05:00-04:00,VIVO,neutral
1313822.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,VIVO,negative
1313823.0,Stocks That Hit 52-Week Highs On Monday,2020-05-11 10:28:00-04:00,VIVO,neutral
1313824.0,"Cannabis Stock Gainers And Losers From May 8, 2020",2020-05-09 07:54:00-04:00,VIVO,negative
1313825.0,Stocks That Hit 52-Week Highs On Friday,2020-05-08 10:32:00-04:00,VIVO,neutral
1313826.0,Meridian Bioscience shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.,2020-05-08 08:35:00-04:00,VIVO,positive
1313827.0,Recap: Meridian Bioscience Q2 Earnings,2020-05-08 08:02:00-04:00,VIVO,neutral
1313828.0,"The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda",2020-05-08 07:59:00-04:00,VIVO,neutral
1313829.0,"Meridian Raises FY20 Guidance: Adj. EPS $0.70-$0.75, Sales $230M-$236M",2020-05-08 07:36:00-04:00,VIVO,neutral
1313830.0,"Meridian Bioscience Q2 EPS $0.230 Beats $0.080 Estimate, Sales $57.300M Beat $49.260M Estimate",2020-05-08 07:36:00-04:00,VIVO,neutral
1313831.0,"Cannabis Stock Gainers And Losers From May 7, 2020",2020-05-07 16:45:00-04:00,VIVO,negative
1313832.0,Stocks That Hit 52-Week Highs On Thursday,2020-05-07 10:33:00-04:00,VIVO,neutral
1313833.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,VIVO,negative
1313834.0,"Cannabis Stock Gainers And Losers From May 6, 2020",2020-05-06 16:57:00-04:00,VIVO,negative
1313835.0,Stocks That Hit 52-Week Highs On Wednesday,2020-05-06 10:43:00-04:00,VIVO,neutral
1313836.0,Meridian Bioscience Partners With QuantuMDx On Coronavirus COVID-19 Assay,2020-05-06 08:07:00-04:00,VIVO,neutral
1313837.0,"ESPAÑOL • Noticias del Día: Una Línea de Ropa de 'Narcos', Alice Moon y el SHC, Acciones de Cannabis, MindMed y el LSD, y Más",2020-05-05 17:55:00-04:00,VIVO,neutral
1313838.0,"Cannabis Stock Gainers And Losers From May 5, 2020",2020-05-05 17:41:00-04:00,VIVO,negative
1313839.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,VIVO,neutral
1313840.0,"Cannabis Stock Gainers And Losers From April 27, 2020",2020-04-27 17:06:00-04:00,VIVO,negative
1313841.0,Meridian Bioscience Shares Volatile On Spike In Volume Following Co. Press Release Highlighting Launch Of Novel Enzyme Master Mix That Eliminates Need To Use RNA Extraction Kit Related To Coronavirus Testing,2020-04-27 11:59:00-04:00,VIVO,positive
1313842.0,"Cannabis Stock Gainers And Losers From April 14, 2020",2020-04-14 20:13:00-04:00,VIVO,negative
1313843.0,Meridian Bioscience Sees Q2 Sales $57M,2020-04-02 07:36:00-04:00,VIVO,neutral
1313844.0,"Cannabis Stock Gainers And Losers From March 23, 2020",2020-03-23 18:54:00-04:00,VIVO,negative
1313845.0,"Cannabis Stock Gainers And Losers From March 17, 2020",2020-03-17 16:50:00-04:00,VIVO,negative
1313846.0,Meridian Bioscience Announces FDA-Clearance For New Curian Analyzer And Curian HpSA Assay,2020-03-16 08:29:00-04:00,VIVO,neutral
1313847.0,"Cannabis Stock Gainers And Losers From March 13, 2020",2020-03-13 17:43:00-04:00,VIVO,negative
1313848.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,VIVO,negative
1313849.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,VIVO,negative
1313850.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,VIVO,negative
1313851.0,Stocks That Hit 52-Week Lows On Wednesday,2020-03-11 11:41:00-04:00,VIVO,negative
1313852.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,VIVO,positive
1313853.0,"Cannabis Stock Gainers And Losers From March, 10. 2020",2020-03-10 19:40:00-04:00,VIVO,negative
1313854.0,50 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-02-28 08:34:00-05:00,VIVO,neutral
1313855.0,"Cannabis Stock Gainers And Losers From Feb. 27, 2020",2020-02-27 17:10:00-05:00,VIVO,negative
1313856.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,VIVO,positive
1313857.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,VIVO,negative
1313858.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,VIVO,negative
1313859.0,"Cannabis Stock Gainers And Losers From Feb. 24, 2020",2020-02-25 07:13:00-05:00,VIVO,negative
1313860.0,"Cannabis Stock Gainers And Losers From Feb. 20, 2020",2020-02-21 09:32:00-05:00,VIVO,negative
1313861.0,"Cannabis Stock Gainers And Losers From Feb. 19, 2020",2020-02-19 16:58:00-05:00,VIVO,negative
1313862.0,Meridian Bioscience Signs Definitive Agreement To Acquire Exalenz Bioscience For $49M,2020-02-19 09:19:00-05:00,VIVO,positive
1313863.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,VIVO,positive
1313864.0,Stocks That Hit 52-Week Lows On Monday,2020-02-10 10:28:00-05:00,VIVO,negative
1313865.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,VIVO,negative
1313866.0,"Meridian Bioscience Q1 Adj. EPS $0.1 Beats $0.07 Estimate, Sales $47.4M Miss $48.9M Estimate",2020-02-07 07:31:00-05:00,VIVO,negative
1313867.0,"Earnings Scheduled For February 7, 2020",2020-02-07 04:02:00-05:00,VIVO,neutral
1313868.0,85 Biggest Movers From Yesterday,2020-02-04 04:56:00-05:00,VIVO,neutral
1313869.0,70 Biggest Movers From Yesterday,2020-01-29 04:40:00-05:00,VIVO,neutral
1313870.0,13 Diagnostics & Research Stocks Moving In Tuesday's Session,2020-01-28 12:55:00-05:00,VIVO,neutral
1313871.0,46 Stocks Moving In Tuesday's Mid-Day Session,2020-01-28 11:50:00-05:00,VIVO,neutral
1313872.0,71 Biggest Movers From Yesterday,2020-01-28 04:14:00-05:00,VIVO,neutral
1313873.0,13 Diagnostics & Research Stocks Moving In Monday's Session,2020-01-27 12:40:00-05:00,VIVO,neutral
1313874.0,40 Stocks Moving In Monday's Mid-Day Session,2020-01-27 11:59:00-05:00,VIVO,neutral
1313875.0,Meridian Bioscience Announces Lyo-Ready 1-Step RT-qPCR Mix Is Used In Development Of Molecular Diagnostics For New Coronavirus Outbreak,2020-01-27 09:30:00-05:00,VIVO,neutral
1313876.0,Stocks That Hit 52-Week Lows On Friday,2019-11-08 11:41:00-05:00,VIVO,negative
1313877.0,94 Biggest Movers From Yesterday,2019-11-08 06:01:00-05:00,VIVO,neutral
1313878.0,75 Stocks Moving In Thursday's Mid-Day Session,2019-11-07 12:19:00-05:00,VIVO,neutral
1313879.0,Meridian Bioscience Sees FY20 Adj. EPS $0.28-$0.34 May Not Compare To $0.51 Est.,2019-11-07 09:32:00-05:00,VIVO,neutral
1313880.0,"Meridian Bioscience Earlier Reported Q4 EPS $0.13 Beats $0.09 Estimate, Sales $50.846M Beat $50.59M Estimate",2019-11-07 09:31:00-05:00,VIVO,neutral
1313881.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,VIVO,negative
1313882.0,Meridian Submits Curian Analyzer And Curian HpSA Assay To The FDA,2019-11-06 07:46:00-05:00,VIVO,neutral
1313883.0,"The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout",2019-10-11 08:14:00-04:00,VIVO,positive
1313884.0,Stocks That Hit 52-Week Lows On Thursday,2019-10-10 11:08:00-04:00,VIVO,negative
1313885.0,Stocks That Hit 52-Week Lows On Wednesday,2019-08-28 11:12:00-04:00,VIVO,negative
1313886.0,Stocks That Hit 52-Week Lows On Monday,2019-08-26 10:28:00-04:00,VIVO,negative
1313887.0,Stocks That Hit 52-Week Lows On Friday,2019-08-23 11:08:00-04:00,VIVO,negative
1313888.0,Stocks That Hit 52-Week Lows On Thursday,2019-08-22 11:12:00-04:00,VIVO,negative
1313889.0,"The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study",2019-08-22 07:18:00-04:00,VIVO,positive
1313890.0,"The Daily Biotech Pulse: Ra Pharma Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform",2019-08-21 07:40:00-04:00,VIVO,neutral
1313891.0,"The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission",2019-08-16 07:33:00-04:00,VIVO,negative
1313892.0,"The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings",2019-08-15 07:45:00-04:00,VIVO,neutral
1313893.0,"The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering",2019-08-14 07:50:00-04:00,VIVO,negative
1313894.0,"The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering",2019-08-08 07:11:00-04:00,VIVO,neutral
1313895.0,Stocks That Fell Through 52-Week Lows Wednesday,2019-08-07 14:22:00-04:00,VIVO,negative
1313896.0,Meridian Bioscience Sees FY19 Adj. EPS $0.63-$0.65 vs $0.56 Est.,2019-07-30 07:41:00-04:00,VIVO,neutral
1313897.0,"Meridian Bioscience Q3 EPS $0.16 Beats $0.09 Estimate, Sales $48.44M Miss $49.81M Estimate",2019-07-30 07:39:00-04:00,VIVO,negative
1313898.0,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",2019-07-30 07:00:00-04:00,VIVO,positive
1313899.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,VIVO,negative
1313900.0,"UPDATE: Canaccord Maintains Sell On Meridian Bioscience, Lowers Target To $9 As Firm Believes 'the turnaround is not near-term and, if one is possible, it is likely at least 2-3 years away'",2019-05-01 11:48:00-04:00,VIVO,negative
1313901.0,"Canaccord Genuity Maintains Sell on Meridian Bioscience Inc. - Common Stock, Lowers Price Target to $9",2019-05-01 10:21:00-04:00,VIVO,negative
1313902.0,10 Biggest Price Target Changes For Wednesday,2019-05-01 09:44:00-04:00,VIVO,neutral
1313903.0,"The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue",2019-05-01 07:39:00-04:00,VIVO,neutral
1313904.0,"Piper Jaffray Upgrades Meridian Bioscience Inc. - Common Stock to Neutral, Lowers Price Target to $11",2019-05-01 06:18:00-04:00,VIVO,negative
1313905.0,68 Biggest Movers From Yesterday,2019-05-01 06:01:00-04:00,VIVO,neutral
1313906.0,50 Stocks Moving In Tuesday's Mid-Day Session,2019-04-30 12:26:00-04:00,VIVO,neutral
1313907.0,"Meridian Bioscience Earlier Reported Q2 Adj. EPS $0.19 Beats $0.16 Estimate, Sales $50.248M Miss $51.74M Estimate; Suspended Qtr. Dividend",2019-04-30 10:39:00-04:00,VIVO,negative
1313908.0,Meridian Bioscience To Acquire Business Of GenePOC; Meridian Will Make $50M Cash Payment At Closing With Future Payments Totalling $70M Contingent Upon Achievement Of Milestones,2019-04-30 10:14:00-04:00,VIVO,neutral
1313909.0,Meridian Bioscience 8-K Shows Purchase Of Most Assets Of GenePoc Canada To Co. For Up To $120M,2019-04-30 08:50:00-04:00,VIVO,positive
1313910.0,"The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering",2019-04-30 08:06:00-04:00,VIVO,positive
1313911.0,Meridian Bioscience Reports Launch Of New Inhibitor Tolerant qPCR Reagent To Significantly Simplify Molecular Diagnostic Workflows From Crude Samples,2019-04-18 08:52:00-04:00,VIVO,negative
1313912.0,"The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio",2019-04-18 07:42:00-04:00,VIVO,neutral
1313913.0,"The Daily Biotech Pulse: Zolgensma Data, Roche Q1 Results, Brainsway IPO",2019-04-17 07:48:00-04:00,VIVO,neutral
1313914.0,"The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Droves, Silk Road, NGM Biopharma To Debut",2019-04-04 07:58:00-04:00,VIVO,neutral
1313915.0,Merdian Bioscience shares are trading lower after Canaccord Genuity downgraded the stock from Hold to Sell.,2019-04-03 09:26:00-04:00,VIVO,neutral
1313916.0,"Benzinga's Top Upgrades, Downgrades For April 3, 2019",2019-04-03 09:16:00-04:00,VIVO,positive
1313917.0,Canaccord Genuity Downgrades Meridian Bioscience to Sell,2019-04-03 06:52:00-04:00,VIVO,neutral
1313918.0,54 Biggest Movers From Yesterday,2019-04-03 05:42:00-04:00,VIVO,neutral
1313919.0,51 Stocks Moving In Tuesday's Mid-Day Session,2019-04-02 12:27:00-04:00,VIVO,neutral
1313920.0,Meridian Bioscience shares are trading lower after the company provided Q2 sales guidance and FY19 EPS guidance below analyst estimates.,2019-04-02 10:25:00-04:00,VIVO,neutral
1313921.0,"Meridian Bioscience Sees Q2 Sales $50M-$56.5M vs $56.37M Est., Sees FY19 Adj. EPS $0.60-$0.65 vs $0.76 Est.",2019-04-02 07:00:00-04:00,VIVO,neutral
1313922.0,"The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial",2019-01-24 07:45:00-05:00,VIVO,negative
1313923.0,Meridian Bioscience Reaffirms FY2019 EPS Guidance of $0.74-0.76 vs $0.76 Est,2019-01-24 07:34:00-05:00,VIVO,neutral
1313924.0,"Meridian Bioscience Q1 EPS $0.20 Beats $0.18 Estimate, Sales $51.48M Miss $53.68M Estimate",2019-01-24 07:32:00-05:00,VIVO,negative
1313925.0,58 Biggest Movers From Yesterday,2019-01-09 05:19:00-05:00,VIVO,neutral
1313926.0,38 Stocks Moving In Tuesday's Mid-Day Session,2019-01-08 12:46:00-05:00,VIVO,neutral
1313927.0,"The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase",2019-01-08 08:15:00-05:00,VIVO,negative
1313928.0,Meridian Bioscience Sees Q1 Sales $51.0M-$51.5M vs $53.5M Est.,2019-01-07 17:19:00-05:00,VIVO,neutral
1313929.0,Meridian Bioscience Reports FDA Clearance For Its New Neonatal Saliva CMV Test,2018-12-06 07:37:00-05:00,VIVO,neutral
1313930.0,Watching Meridian Biosciences Shares Amid Report FDA Authorized Test To Aid In Detecting A Type Of Herpes Virus In Newborns Called Cytomegalovirus,2018-11-30 15:58:00-05:00,VIVO,positive
1313931.0,"Stocks Trading Ex Dividend For Fri., Nov. 16, 2018",2018-11-16 10:34:00-05:00,VIVO,neutral
1313932.0,"Stocks That Will Be Trading Ex Dividend Fri., Nov. 16, 2018",2018-11-15 11:35:00-05:00,VIVO,neutral
1313933.0,"The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall",2018-11-09 07:32:00-05:00,VIVO,neutral
1313934.0,80 Biggest Movers From Yesterday,2018-11-09 05:18:00-05:00,VIVO,neutral
1313935.0,"Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 7, 2018",2018-11-08 10:52:00-05:00,VIVO,neutral
1313936.0,Meridian Bioscience Sees FY19 EPS $0.74-$0.76 vs $0.77 Est.,2018-11-08 07:41:00-05:00,VIVO,neutral
1313937.0,"Meridian Bioscience Inc. Q4 EPS $0.20 Beats $0.16 Estimate, Sales $53.1M Beat $51.11M Estimate",2018-11-08 07:36:00-05:00,VIVO,neutral
1313938.0,DiaSorin And Meridian Enter Into Strategic Collaboration To Sell Helicobacter Pylori Stool Antigen Test In US And UK,2018-10-09 16:05:00-04:00,VIVO,neutral
1313939.0,Meridian Bioscience Reports Chair John Kraeutler To Retire; David Phillips Name Replacement,2018-09-24 16:00:00-04:00,VIVO,neutral
1313940.0,"Stocks Trading Ex Dividend For Thurs., Aug. 9, 2018",2018-08-09 08:42:00-04:00,VIVO,neutral
1313941.0,"Stocks Which Will Trade Ex Dividend On Thurs., Aug. 9, 2018",2018-08-08 11:48:00-04:00,VIVO,neutral
1313942.0,"Meridian Bioscience Q3 EPS $0.18 Misses $0.23 Estimate, Sales $51.737M Miss $52.12M Estimate",2018-07-31 07:35:00-04:00,VIVO,negative
1313943.0,"FDA Announces Revised Guidance On Testing Of Donated Blood, Blood Components For Zika",2018-07-06 10:14:00-04:00,VIVO,neutral
1313944.0,"Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading",2018-06-20 08:36:00-04:00,VIVO,negative
1313945.0,"Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares",2018-06-19 08:08:00-04:00,VIVO,positive
1313946.0,"Meridian Introduces Critical Raw Materials for Nipah Virus Diagnosis, a Key Emerging Disease on the WHO's Priority List",2018-05-30 10:55:00-04:00,VIVO,negative
1313947.0,"Meridian Bioscience Q2 Adj. EPS $0.27 Beats $0.21 Est., Sales $56.5M Beats $55M Est.",2018-04-26 07:36:00-04:00,VIVO,neutral
1313948.0,Meridian Shares Volatile As FDA Concludes Studies Performed By BD Were Robust & Showed There Was A Significant Chance Of False Results With Magellan's Leadcare Tests; Continues To Recommend That Magellan Lead Tests Not Be Used With Blood Samples From Vein,2018-03-22 14:57:00-04:00,VIVO,positive
1313949.0,"Meridian Bioscience Realigns Organizational Structure, New Structure Consists of two Business Units, Diagnostics and Life Science, Supported by a Global Corporate Team",2018-03-21 07:31:00-04:00,VIVO,positive
1313950.0,"Meridian Bioscience Reports Q4 EPS $0.15 vs $0.15 Est., Sales $52.28M vs $49.00M Est.",2018-01-25 07:16:00-05:00,VIVO,neutral
1313951.0,Meridian Bioscience S-3 Filing Shows Registration For $100M Mixed Securities Shelf Offering,2017-11-29 09:37:00-05:00,VIVO,positive
1313952.0,"Meridian Reaffirms FY18 Adj. EPS $0.65-$0.68 vs $0.68 Est., Sales $207M-$212M vs $204.7M Est.",2017-11-09 07:33:00-05:00,VIVO,neutral
1313953.0,"Meridian Bioscience Reports Q4 Adj. EPS $0.15, Inline, Sales $49.7M vs $48M Est.",2017-11-09 07:32:00-05:00,VIVO,neutral
1313954.0,UPDATE: Meridian Says 'Magellan will promptly submit a response to the Warning Letter for the Agency's consideration',2017-10-23 17:31:00-04:00,VIVO,negative
1313955.0,Meridian Bioscience Offers Comment Related To FDA Statement Regarding Warning Letter Issued To Magellan Diagnostics,2017-10-23 17:30:00-04:00,VIVO,negative
1313956.0,Weakness In Meridian Bioscience Is Being Attributed To A FDA Warning Letter Regarding An Inspection Of The Company's Manufacturing,2017-10-23 13:24:00-04:00,VIVO,negative
1313957.0,Meridian Bioscience Sees fy EPS $0.66-0.67 vs $0.67 Est; Sees Sales $200.50M vs $198.35M Est,2017-10-19 07:36:00-04:00,VIVO,neutral
1313958.0,"Meridian Bioscience, Inc. Names Jack Kenny CEO",2017-10-10 11:51:00-04:00,VIVO,neutral
1313959.0,"Meridian Bioscience CEO Kraeutler Buys 7,000 @ Avg Price: $13.67 -Form4",2017-08-25 12:14:00-04:00,VIVO,neutral
1313960.0,Meridian Bioscience Reports Initiation Of Clinical Trials For New Neonatal Saliva CMV illumigne Test,2017-08-09 13:33:00-04:00,VIVO,neutral
1313961.0,"Meridian Biosciences Reports Q3 Adj. EPS $0.16 vs $0.17 Est., Sales $50.14M vs $49.2M Est.",2017-07-27 07:48:00-04:00,VIVO,neutral
1313962.0,"UPDATE: Meridian, Magellan Reiterate Mutual Commitment To Strengthening Magellan's Quality System, Ensuring All Aspects Of System Are In Full Compliance",2017-07-13 13:41:00-04:00,VIVO,positive
1313963.0,UPDATE: Meridian Says Magellan Will Promptly Submit Responses To Form FDA-483,2017-07-13 13:40:00-04:00,VIVO,neutral
1313964.0,UPDATE: Meridian Highlights Form Represents Investigators' Observations And Is Not A Final Agency Determination,2017-07-13 13:39:00-04:00,VIVO,negative
1313965.0,Meridian Bioscience Issues Comment Related To FDA Press Statement,2017-07-13 13:38:00-04:00,VIVO,neutral
1313966.0,"FDA Says Design Validation For Magellan Diagnostics' Leadcare Test Systems Did Not Ensure Device Conforms To Defined User Needs and Intended Uses, Inspected Facility In North Billerica, Massachusetts",2017-07-13 11:03:00-04:00,VIVO,negative
1313967.0,"CORRECTION: Magellan Health Is Not Related To FDA 483 Doc; Meridian Bioscience Is Owner Of Magellan Diagnostics, The Co. Facility In Question In FDA 483 Doc",2017-07-13 10:49:00-04:00,VIVO,neutral
1313968.0,"UPDATE: Observations In FDA 483 Doc On Magellan's North Billerica Facility Include Questions On Design Validation, Inadequate Risk Analysis, Procedures For Corrective, Preventive Action Not Adequately Establish",2017-07-13 10:45:00-04:00,VIVO,negative
1313969.0,Watching Meridian Bioscience Shares As Traders Circulating FDA 483 Form Including 9 Observations About Magellan's North Billerica Facility; BZ NOTE: Meridian Is Owner Of Magellan,2017-07-13 10:44:00-04:00,VIVO,positive
1313970.0,UPDATE: Meridian Says '[Co.] and Magellan continue to take these matters very seriously and will continue to work closely and fully with the FDA and CDC to address the concerns identified as quickly as possible.',2017-06-30 12:05:00-04:00,VIVO,negative
1313971.0,UPDATE: Meridian Says FDA Concluded Inspection On Magellan's Quality System; Magellan Is Committed To Addressing FDA Investigators' Observations,2017-06-30 12:04:00-04:00,VIVO,positive
1313972.0,Meridian Bioscience Offers Comments On Recent FDA Matters Related To Magellan Diagnostics,2017-06-30 12:03:00-04:00,VIVO,neutral
1313973.0,"Meridian Bioscience Says They Are Going To Continue Working With The FDA, Doesn't Expect Recall To Cause Any Material Effect To Financial Results",2017-06-06 14:28:00-04:00,VIVO,neutral
1313974.0,"FDA Says Meridian Bioscience's Magellan Diagnostics Expands Recall For Leadcare Testing Systems Due To Inaccurate Test Results, Class I Recall",2017-06-05 16:50:00-04:00,VIVO,positive
1313975.0,"Meridian Bioscience Comments on Matter Involving its Subsidiary, Magellan Diagnostics via FDA",2017-05-17 15:31:00-04:00,VIVO,neutral
1313976.0,15 Biggest Mid-Day Losers For Wednesday,2017-05-17 12:49:00-04:00,VIVO,negative
1313977.0,Meridian Bioscience Shares Plunge as FDA Issues Warning Certain Lead Tests by Co.'s Magellan Diagnostics Could Provide Inaccurate Results,2017-05-17 09:01:00-04:00,VIVO,positive
1313978.0,"Meridian Bioscience Reports Retirement of CEO John Kraeutler, Engaged Korn Ferry to Conduct Search",2017-05-10 09:03:00-04:00,VIVO,positive
1313979.0,"Meridian Reports Q2 EPS $0.22, Inline, Sales $54.125M vs $51.259M in Same Qtr. Last Year",2017-04-27 07:50:00-04:00,VIVO,neutral
1313980.0,Meridian Bioscience Reports Launch of TruQuick Rapid Tests for Asia Pacific,2017-02-03 10:57:00-05:00,VIVO,neutral
1313981.0,Mid-Afternoon Market Update: Seagate Climbs On Strong Q2 Results; Meridian Bioscience Shares Plummet,2017-01-25 15:03:00-05:00,VIVO,positive
1313982.0,15 Biggest Mid-Day Losers For Wednesday,2017-01-25 13:45:00-05:00,VIVO,negative
1313983.0,Mid-Day Market Update: Dow Surges Over 150 Points; Arctic Cat Shares Rise On Acquisition News,2017-01-25 12:21:00-05:00,VIVO,positive
1313984.0,Mid-Morning Market Update: Markets Open Higher; Boeing Profit Beats Views,2017-01-25 10:04:00-05:00,VIVO,positive
1313985.0,Meridian Biosciences Shares to Resume Trade at 8 a.m. EST,2017-01-25 07:35:00-05:00,VIVO,positive
1313986.0,"UPDATE: Meridian Bioscience Lowers FY17 Guidance From $205-$210 To $193-$199M, EPS From $0.82-$0.85 To $0.64-$0.69",2017-01-25 07:32:00-05:00,VIVO,negative
1313987.0,UPDATE: Meridian Reduces Qtr. Dividend From $0.20 To $0.125/Share,2017-01-25 07:32:00-05:00,VIVO,neutral
1313988.0,"Meridian Bioscience Reports Q1 EPS $0.15 vs $0.21 in Same Qtr. Last Year, Sales $46.809vs $47.16M Est.",2017-01-25 07:31:00-05:00,VIVO,neutral
1313989.0,"Meridian Bioscience Reduces Cash Dividend, Revises Guidance Downward",2017-01-25 07:31:00-05:00,VIVO,neutral
1313990.0,Meridian Bioscience Halted News Pending,2017-01-25 07:25:00-05:00,VIVO,neutral
1313991.0,Meridian Bioscience Signs Exclusive Partnership With MedCaptain Medical Technology To Increase Blood Lead Testing In China,2016-12-20 14:01:00-05:00,VIVO,positive
1313992.0,"MERIDIAN BIOSCIENCE INC: Ellingwood Dwight E (Director) Buys 1,020 @ Avg Price: $17.12 (Form4)",2016-12-01 11:36:00-05:00,VIVO,neutral
1313993.0,"10 Notable Stocks Trading Ex-Dividend Thursday, November 17",2016-11-16 11:32:00-05:00,VIVO,neutral
1313994.0,"Meridian Bioscience Reports Q4 EPS $0.14 vs. Est. $0.14, Rev. $46.9M vs. Est. $47.7M",2016-11-10 07:54:00-05:00,VIVO,neutral
1313995.0,"Meridian Bioscience CEO Kraeutler Buys 5,000 Shares @$16.13/Share -Form 4",2016-11-07 12:54:00-05:00,VIVO,positive
1313996.0,"Meridian Bioscience VP Baldini Buys 4,900 Shares @$16.00/Share -Form 4",2016-11-07 12:52:00-05:00,VIVO,positive
1313997.0,15 Biggest Mid-Day Losers For Wednesday,2016-10-19 12:36:00-04:00,VIVO,negative
1313998.0,Stocks Hitting 52-Week Lows,2016-10-19 10:19:00-04:00,VIVO,negative
1313999.0,Mid-Morning Market Update: Markets Mostly Higher; Morgan Stanley Tops Q3 Estimates,2016-10-19 09:55:00-04:00,VIVO,positive
1314000.0,"Meridian Bioscience Sees FY17 Sales $205M-$210M vs $210.6M Est., EPS $0.81-$0.85 vs $0.91 Est.",2016-10-18 16:32:00-04:00,VIVO,neutral
1314001.0,Meridian Bioscience Sees Q4 Sales ~$47M vs $49.3M Est.,2016-10-18 16:31:00-04:00,VIVO,neutral
1314002.0,"Meridian Bioscience Sees FY16 Sales ~$196M vs $198.5M Est., EPS $0.75-$0.76 vs $0.86 Est.",2016-10-18 16:31:00-04:00,VIVO,neutral
1314003.0,Magellan Diagnostics Receives CFDA Clearance for LeadCare II in China,2016-08-09 15:45:00-04:00,VIVO,neutral
1314004.0,Meridian Bioscience Reports LeadCare II Received CFDA Clearance,2016-08-09 15:00:00-04:00,VIVO,neutral
1314005.0,Hilliard Lyons Downgrades Meridian Bioscience to Hold,2016-07-29 09:31:00-04:00,VIVO,neutral
1314006.0,"Meridian Bioscience Sees Fy16 Rev. $195-$200M vs. Est. $203M, EPS $0.86-$0.90 vs. Est. $0.88",2016-07-28 08:14:00-04:00,VIVO,neutral
1314007.0,"Meridian Bioscience Reports Q3 EPS $0.21 vs. Est. $0.22, Rev. $50.7M vs. Est. $52.8M",2016-07-28 08:13:00-04:00,VIVO,neutral
1314008.0,Sectors and Stocks To Watch If Hillary Clinton Is Elected,2016-07-07 16:52:00-04:00,VIVO,neutral
1314009.0,"Meridian Bioscience, Inc. Receives FDA Clearance for New Molecular Test for the Detection of Mycoplasma pneumoniae",2016-06-15 08:30:00-04:00,VIVO,neutral
1314010.0,"Bioline, Meridian Bioscience Subsidiary, Launches New MyTaq Plant-PCR Kit",2016-06-02 07:04:00-04:00,VIVO,neutral
1314011.0,"Meridian Bioscience Sees FY16 EPS $0.86-$0.90  vs. Est. $0.89, Rev. $195-$200M vs. Est. $201M",2016-04-28 07:55:00-04:00,VIVO,neutral
1314012.0,"Meridian Bioscience Reports Q2 EPS $0.24 vs. Est. $0.24, Rev. $51.3M vs. Est. $52M",2016-04-28 07:54:00-04:00,VIVO,neutral
1314013.0,UPDATE: Hilliard Lyons Expects VIVO Margins To Take A Hit But Will Be Offset By Additional Revenues,2016-03-28 12:23:00-04:00,VIVO,neutral
1314014.0,"Hilliard Lyons Upgrades Meridian Bioscience to Buy, Announces $22.00 PT",2016-03-28 12:21:00-04:00,VIVO,neutral
1314015.0,Meridian Bioscience Acquires Magellan Biosciences For $666M,2016-03-24 16:16:00-04:00,VIVO,neutral
1314016.0,Hilliard Lyons Downgrades Meridian Bioscience to Neutral,2016-03-21 09:52:00-04:00,VIVO,neutral
1314017.0,"Meridian Bioscience Reaffirms FY16 Outlook: EPS $0.86-$0.90 vs $0.88 Est., Sales $195M-$200M vs $187.9M Est.",2016-01-27 07:31:00-05:00,VIVO,neutral
1314018.0,"Meridian Bioscience Reports Q1 EPS $0.21, Inline, Sales $47.2M vs $48.6M Est.",2016-01-27 07:30:00-05:00,VIVO,neutral
1314019.0,"Meridian Bioscience, Lean Continuous Improvement Partner For  Launch of illumigene Malria",2016-01-26 10:04:00-05:00,VIVO,positive
1314020.0,Meridian Receives FDA Clearance for New Molecular Whooping Cough Test Claims,2015-11-18 13:01:00-05:00,VIVO,neutral
1314021.0,UPDATE: Meridian Bioscience Announces Investment in Oasis Diagnostics; Terms Not Disclosed,2015-11-12 15:02:00-05:00,VIVO,neutral
1314022.0,"Meridian Bioscience Reports Investment in Oasis Diagnostics, No Terms Disclosed",2015-11-12 15:01:00-05:00,VIVO,negative
1314023.0,"Meridian Bioscience Reports Q4 EPS $0.20 Vs Est $0.21, Sales $47.1M Vs Est $46.64M",2015-11-05 07:34:00-05:00,VIVO,neutral
1314024.0,Top 4 Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2015-09-16 04:09:00-04:00,VIVO,negative
1314025.0,"Meridian Bioscience Sees FY16 EPS $0.86-$0.90 vs $0.93 Est., Sales $195M-$200M vs $203.5M Est.",2015-09-09 07:02:00-04:00,VIVO,neutral
1314026.0,Bioline Launches New EPIK miRNA Panel Assays,2015-09-04 10:41:00-04:00,VIVO,neutral
1314027.0,Meridian Bioscience Given FDA Clearance for New Molecular Amplification Test: illumigene HSV 1&2,2015-07-20 09:24:00-04:00,VIVO,neutral
1314028.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Operating Margin,2015-06-23 05:01:00-04:00,VIVO,positive
1314029.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS,2015-06-08 04:14:00-04:00,VIVO,positive
1314030.0,Meridian Bioscience Reports Launch of Para-Pak SVT,2015-06-04 10:00:00-04:00,VIVO,neutral
1314031.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROI,2015-05-13 04:45:00-04:00,VIVO,positive
1314032.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROA,2015-05-05 04:51:00-04:00,VIVO,positive
1314033.0,"Meridian Bioscience Board Succession Hints At M&A Appetite Change, Canaccord Says",2015-05-04 12:32:00-04:00,VIVO,positive
1314034.0,"Meridian Bioscience Reports Inline Q2 EPS $0.24, Sales $51.5M Vs Est $50.43, Backs Guidance FOr FY 2015 EPS $0.85-$0.91 & Revs $193M-$200M",2015-04-23 07:34:00-04:00,VIVO,negative
1314035.0,Meridian Bioscience Receives CE Marking For 2 New Molecular Amplification Tests,2015-02-26 08:33:00-05:00,VIVO,neutral
1314036.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest EPS,2015-02-12 04:23:00-05:00,VIVO,positive
1314037.0,"Craig-Hallum Upgrades Meridian Bioscience to Buy, Raises PT to $22.00",2015-01-23 09:29:00-05:00,VIVO,neutral
1314038.0,"Meridian Bioscience Reports Q1 EPS $0.19, Inline, Sales $48M vs $46M Est.",2015-01-22 08:03:00-05:00,VIVO,neutral
1314039.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROI,2015-01-22 04:20:00-05:00,VIVO,positive
1314040.0,"Earnings Scheduled For January 21, 2015",2015-01-21 04:51:00-05:00,VIVO,neutral
1314041.0,Benzinga's Top Downgrades,2015-01-02 09:28:00-05:00,VIVO,positive
1314042.0,Raymond James Downgrades Meridian Bioscience  To Underperform,2015-01-02 07:45:00-05:00,VIVO,neutral
1314043.0,Raymond James Downgrades Meridian Bioscience to Underperform,2015-01-02 05:46:00-05:00,VIVO,neutral
1314044.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2014-12-31 04:25:00-05:00,VIVO,negative
1314045.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROI,2014-12-18 04:44:00-05:00,VIVO,positive
1314046.0,Meridian Life Science Awarded SBIR II by CDC to Develop Rotavirus Vaccine,2014-12-02 06:03:00-05:00,VIVO,positive
1314047.0,Filing from Meridian Bioscience Shows Registration for Automatic Mixed Securities Shelf Offering,2014-12-01 10:52:00-05:00,VIVO,positive
1314048.0,Meridian Bioscience Inc. Reports Q4 EPS of $0.20 vs $0.22 Est,2014-11-06 07:35:00-05:00,VIVO,neutral
1314049.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS,2014-10-08 04:49:00-04:00,VIVO,positive
1314050.0,"Meridian Bioscience Reports Deal with Premier Inc., Will Offer Hospitals Molecular Diagnostic Tests",2014-09-03 07:31:00-04:00,VIVO,neutral
1314051.0,Meridian Bioscience Inc. Sees FY2015 EPS $0.85-0.91 vs $0.97 Est; Sees Sales $193.0M-200.0M vs $203.80M Est,2014-09-02 07:32:00-04:00,VIVO,neutral
1314052.0,Meridian Bioscience Inc. Reports Q2 EPS of $0.21 vs $0.23 Est; Revenue of $47.20M vs $47.96M Est,2014-07-24 08:16:00-04:00,VIVO,neutral
1314053.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROI,2014-07-14 04:55:00-04:00,VIVO,positive
1314054.0,"Meridian Bioscience Announces License Approval for illumigene Mycoplasma, Pertussis from Health Canada",2014-05-28 11:31:00-04:00,VIVO,positive
1314055.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROE,2014-05-05 05:10:00-04:00,VIVO,positive
1314056.0,Meridian Bioscience Raises Qtrly Dividend 5% to $0.20/Share,2014-04-24 07:40:00-04:00,VIVO,neutral
1314057.0,Meridian Bioscience Inc. Reports Q2 EPS of $0.24 vs $0.27 Est; Revenue of $50.10M vs $52.18M Est,2014-04-24 07:36:00-04:00,VIVO,neutral
1314058.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest EPS,2014-04-23 04:43:00-04:00,VIVO,positive
1314059.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROA,2014-04-11 04:41:00-04:00,VIVO,positive
1314060.0,"Meridian Bioscience Receives FDA Clearance for Illumigene Pertussis, Will Be Available Within a Month",2014-03-27 14:07:00-04:00,VIVO,neutral
1314061.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates,2014-03-20 04:29:00-04:00,VIVO,positive
1314062.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2014-02-13 04:18:00-05:00,VIVO,negative
1314063.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue,2014-01-30 04:47:00-05:00,VIVO,positive
1314064.0,"Top Four Stocks for Income During Period of Low Interest Rates, Bond Yields",2014-01-23 15:09:00-05:00,VIVO,positive
1314065.0,Meridian Bioscience Raises Dividend to $0.20,2014-01-22 07:33:00-05:00,VIVO,neutral
1314066.0,Meridian Bioscience Inc. Sees FY2014 EPS $0.98-1.03 vs $0.99 Est,2014-01-22 07:33:00-05:00,VIVO,neutral
1314067.0,"Meridian Bioscience Inc. Reports Q1 EPS of $0.18, Inline; Revenue of $44.80M vs $47.59M Est",2014-01-22 07:33:00-05:00,VIVO,neutral
1314068.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS,2014-01-15 04:10:00-05:00,VIVO,positive
1314069.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROA,2013-12-30 06:12:00-05:00,VIVO,positive
1314070.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue,2013-12-18 04:28:00-05:00,VIVO,positive
1314071.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Revenue,2013-12-03 04:26:00-05:00,VIVO,positive
1314072.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue Estimates,2013-11-12 06:28:00-05:00,VIVO,positive
1314073.0,Meridian Bioscience Inc. Sees FY2014 EPS $0.98-1.03 vs $1.00 Est; Sees Sales $203.0M-208.0M vs $205.05M Est,2013-11-07 07:40:00-05:00,VIVO,neutral
1314074.0,Meridian Bioscience Inc. Reports Q4 EPS of $0.22 vs $0.23 Est; Revenue of $49.0M vs $49.24M Est,2013-11-07 07:39:00-05:00,VIVO,neutral
1314075.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Operating Margin,2013-11-06 05:20:00-05:00,VIVO,positive
1314076.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2013-11-01 04:26:00-04:00,VIVO,negative
1314077.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue,2013-10-21 06:50:00-04:00,VIVO,positive
1314078.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2013-10-01 03:17:00-04:00,VIVO,negative
1314079.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Profit Margin,2013-09-19 04:12:00-04:00,VIVO,positive
1314080.0,"Meridian Bioscience Shares Volatile But Largely Unch Following News FY13 Sales Will Be at Low-End of Prior Range, FY14 Sales Expected $203-208M vs $205.6M Est, EPS $0.98-1.03 vs $1.01 Est.",2013-09-09 10:13:00-04:00,VIVO,positive
1314081.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Operating Margin,2013-09-03 05:09:00-04:00,VIVO,positive
1314082.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2013-08-19 04:10:00-04:00,VIVO,negative
1314083.0,Meridian Life Science® Successfully Manufactures Influenza Challenge Stock for Immune Targeting Systems ,2013-07-30 07:00:00-04:00,VIVO,positive
1314084.0,"Wedbush Upgrades Meridian Bioscience Inc. to Neutral, Raises PT to $21.00",2013-07-26 07:55:00-04:00,VIVO,neutral
1314085.0,Meridian Bioscience Inc. Reports Q2 EPS of $0.24 vs $0.22 Est; Revenue of $47.10M vs $46.96M Est,2013-07-25 07:32:00-04:00,VIVO,neutral
1314086.0,UPDATE: Cowen and Company Downgrades Meridian Bioscience on Tough Road Ahead,2013-07-16 11:25:00-04:00,VIVO,negative
1314087.0,"Cowen & Company Downgrades Meridian Bioscience Inc. to Market Perform, Lowers PT to $21.00",2013-07-16 08:47:00-04:00,VIVO,negative
1314088.0,UPDATE: Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene Mycoplasma ,2013-06-10 10:31:00-04:00,VIVO,neutral
1314089.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2013-04-30 04:19:00-04:00,VIVO,negative
1314090.0,Stocks Going Ex Dividend the First Week of May,2013-04-29 10:30:00-04:00,VIVO,neutral
1314091.0,"Craig-Hallum Downgrades Meridian Bioscience Inc. to Hold, Lowers PT to $22.00",2013-04-26 07:42:00-04:00,VIVO,negative
1314092.0,"Meridian Bioscience Inc. Reports Q2 EPS of $0.24, Inline; Revenue of $47.30M vs $49.66M Est",2013-04-25 07:15:00-04:00,VIVO,neutral
1314093.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Operating Margin,2013-04-18 06:01:00-04:00,VIVO,positive
1314094.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Revenue,2013-03-20 04:13:00-04:00,VIVO,positive
1314095.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates For The Next Quarter,2013-02-21 04:21:00-05:00,VIVO,positive
1314096.0,"Meridian Subsidiary Bioline, Launches ISOLATE II",2013-02-06 07:10:00-05:00,VIVO,negative
1314097.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Revenue Estimates,2013-01-24 02:05:00-05:00,VIVO,positive
1314098.0,"Canaccord Genuity Maintains Hold on Meridian Bioscience Inc., Raises PT to $20.00",2013-01-23 16:24:00-05:00,VIVO,neutral
1314099.0,Meridian Bioscience Inc. Reports Q1 EPS of $0.20 vs $0.19 Est; Revenue of $45.40M vs $44.34M Est,2013-01-23 07:36:00-05:00,VIVO,neutral
1314100.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Profit Margin,2013-01-08 04:02:00-05:00,VIVO,positive
1314101.0,Top 4 Stocks In The Diagnostic Substances Industry With The Highest Profit Margin,2012-12-20 03:01:00-05:00,VIVO,positive
1314102.0,"UPDATE: Wedbush Securities Downgrades Meridian Bioscience to Underperform, Reiterates $17 PT",2012-11-28 11:08:00-05:00,VIVO,positive
1314103.0,"UPDATE: Wedbush Downgrades Meridian Bioscience to Underperform, Maintains PT to $17.0",2012-11-28 08:39:00-05:00,VIVO,neutral
1314104.0,Wedbush Downgrades Meridian Bioscience Inc. ,2012-11-28 07:40:00-05:00,VIVO,neutral
1314105.0,Meridian Bioscience Reports Q4 EPS $0.21 vs $0.19 Est; Revenues $43.7M vs $42.97M Est,2012-11-08 07:44:00-05:00,VIVO,neutral
1314106.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROE,2012-10-24 03:29:00-04:00,VIVO,positive
1314107.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates,2012-10-10 02:07:00-04:00,VIVO,positive
1314108.0,Cowen Initiates Coverage Meridian Bioscience at Outperform,2012-10-02 08:15:00-04:00,VIVO,neutral
1314109.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Profit Margin,2012-09-21 01:48:00-04:00,VIVO,positive
1314110.0,Meridian bioscience Gets FDA Clearance for New Molecular Test illumigene Group A Strep,2012-09-17 15:48:00-04:00,VIVO,neutral
1314111.0,Meridian Guides FY 2013 Revenue $190M-195M; FY EPS $0.86-0.91,2012-08-28 07:35:00-04:00,VIVO,neutral
1314112.0,Wedbush Securities Upgrades Meridian Bioscience from Underperform to Neutral,2012-07-31 07:29:00-04:00,VIVO,positive
1314113.0,UPDATE: Canaccord Genuity Downgrades Meridian Bioscience to Hold on FQ3 Report   ,2012-07-27 11:15:00-04:00,VIVO,neutral
1314114.0,"Canaccord Downgrades Meridian Bioscience from Buy to Hold, Lowers PT from $25 to $18",2012-07-27 06:02:00-04:00,VIVO,negative
1314115.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue,2012-07-11 02:57:00-04:00,VIVO,positive
1314116.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Profit Margin,2012-05-14 02:20:00-04:00,VIVO,positive
1314117.0,Meridian Bioscience Reports Q2 EPS $0.23 vs $0.21 Est; Revenues $47.4M vs $44.81M Est,2012-04-26 08:10:00-04:00,VIVO,neutral
1314118.0,Meridian Bioscience Awarded New Agreement with Premier Healthcare Alliance for Molecular Diagnostic Tests and Instruments for C,2012-04-12 17:04:00-04:00,VIVO,positive
1314119.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2012-03-30 05:16:00-04:00,VIVO,negative
1314120.0,"Financial Breakfast: Morning News Summary for March 21, 2012",2012-03-21 07:18:00-04:00,VIVO,neutral
1314121.0,Bioline Receives Clearance from TGA for the Commercialization in Australia of the New Molecular Test illumigene® Group B Streptococcus   ,2012-03-21 07:00:00-04:00,VIVO,neutral
1314122.0,Meridian Bioscience Receives FDA Clearance for New Legionella Test,2012-02-27 13:00:00-05:00,VIVO,neutral
1314123.0,Top 4 Stocks In The Diagnostic Substances Industry With The Highest Profit Margin,2012-02-27 04:46:00-05:00,VIVO,positive
1314124.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2012-02-13 05:07:00-05:00,VIVO,negative
1314125.0,UPDATE: Wedbush Downgrades Meridian Bioscience to Underperform,2012-01-31 09:52:00-05:00,VIVO,neutral
1314126.0,Wedbush Downgrades Meridian Bioscience to Underperform,2012-01-31 07:29:00-05:00,VIVO,neutral
1314127.0,Meridian Bioscience Receives FDA Clearance For ImmunoCard C. difficile GDH Test,2011-12-27 11:16:00-05:00,VIVO,neutral
1314128.0,Meridian Bioscience Receives FDA Clearance for New Molecular Test: illumigene Group B Streptococcus,2011-12-12 09:30:00-05:00,VIVO,neutral
1314129.0,Meridian Bioscience Files Automatic Mixed Securities Shelf,2011-11-29 11:46:00-05:00,VIVO,positive
1314130.0,Piper Jaffray Remains Underweight On Meridian Biosciences,2011-11-10 12:53:00-05:00,VIVO,neutral
1314131.0,Meridian Bioscience Reports Q3 EPS $0.18 vs $0.19 Est; Revenues $41.30M vs $42.11M Est,2011-11-10 07:31:00-05:00,VIVO,neutral
1314132.0,Wedbush Lowers PT on Meridian Bioscience to $16,2011-11-07 12:27:00-05:00,VIVO,negative
1314133.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue,2011-09-20 03:19:00-04:00,VIVO,positive
1314134.0,Piper Jaffray Underweight On Meridian Bioscience ,2011-09-13 07:51:00-04:00,VIVO,neutral
1314135.0,"Piper Jaffray Initiates Meridian Bioscience At Underweight, $14 PT",2011-09-13 06:12:00-04:00,VIVO,neutral
1314136.0,UPDATE: Meridian Bioscience Sees FY2012 EPS of $0.85-0.89 vs $0.87,2011-08-25 11:03:00-04:00,VIVO,neutral
1314137.0,UPDATE: Meridian Bioscience Sees FY2012 Sales of $183-192M vs 184.18M,2011-08-25 11:02:00-04:00,VIVO,neutral
1314138.0,Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2012 and Comments on Fiscal 2011 Guidance ,2011-08-25 11:00:00-04:00,VIVO,neutral
1314139.0,Meridian Bioscience Launches ImmunoCard C. difficile GDH Assay in Europe   ,2011-08-09 15:47:00-04:00,VIVO,neutral
1314140.0,Biggest Losers in Pre-Market Trading,2011-07-21 09:00:00-04:00,VIVO,negative
1314141.0,Stocks to Watch for Wednesday 7/20/2011: Fresh 52 Week Highs and Lows,2011-07-20 01:51:00-04:00,VIVO,positive
1314142.0,Stocks to Watch for Monday 7/18/2011: Fresh 52 Week Highs and Lows,2011-07-17 21:10:00-04:00,VIVO,positive
1314143.0,Meridian Tests Detect Deadly Toxins Produced by E. coli O104 Outbreak Strain ,2011-06-10 12:16:00-04:00,VIVO,negative
1314144.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROE,2011-06-07 01:41:00-04:00,VIVO,positive
1314145.0,"Top 4 Small-Cap Stocks In The Diagnostic Substance Industry With The Highest Operating Margin (AXK, BLUD, VIVO, NEOG)",2011-05-17 00:25:00-04:00,VIVO,positive
1314146.0,Meridian Bioscience Receives FDA Clearance for New Premier C. difficile GDH Assay ,2011-05-10 13:30:00-04:00,VIVO,neutral
1314147.0,"Market Analysts coverage on 5/10/11- NRG, OLP, RIO, TAL, TRGP, VIVO, VRX, VVC, AAUKY, BHP, BOBE, CEPH, CSCO, CZZ, GPK, MDVN, NGLS, NNA",2011-05-10 10:14:00-04:00,VIVO,neutral
1314148.0,Meridian Bioscience Reports Q2 EPS $0.20 ex-items vs. $0.20; Revenues $41.1M vs. $41.2M Est. (VIVO),2011-04-21 07:22:00-04:00,VIVO,neutral
1314149.0,"Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue (BLUD, NEOG, ABAX, VIVO)",2011-04-14 03:03:00-04:00,VIVO,positive
1314150.0,"Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates (DBD, NEOG, VIVO, ABAX)",2011-04-06 01:42:00-04:00,VIVO,positive
1314151.0,Canaccord Ups VIVO To Buy,2011-03-24 06:49:00-04:00,VIVO,neutral
1314152.0,Meridian Bioscience Receives FDA Clearance For New illumigene C. difficile Pediatric Claim   ,2011-03-02 15:00:00-05:00,VIVO,neutral
1314153.0,Meridian Misses on Lower Flu Sales - Analyst Blog,2011-01-24 11:31:00-05:00,VIVO,negative
1314154.0,Meridian Misses on Lower Flu Sales - Analyst Blog,2011-01-24 11:15:00-05:00,VIVO,negative
1314155.0,"Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Profit Margin (TRIB, AXK, BLUD, VIVO)",2011-01-18 03:22:00-05:00,VIVO,positive
1314156.0,Bearish MACD for VIVO - Tale of the Tape,2011-01-13 11:31:00-05:00,VIVO,neutral
1314157.0,Bearish MACD for VIVO - Tale of the Tape,2011-01-13 11:17:00-05:00,VIVO,neutral
1314158.0,"Top 4 Stocks In The Diagnostic Substances Industry With The Highest Profit Margin (TRIB, BLUD, VIVO, QDEL)",2010-11-17 03:58:00-05:00,VIVO,positive
1314159.0,VCA ANTECH INC (WOOF) - Profit Tracks,2010-09-17 09:03:00-04:00,VIVO,positive
1314160.0,"Zacks Sell List Highlights: Revlon, VCA Antech, Meridian Bioscience and Stillwater Mining Company   - Press Releases",2010-09-16 11:42:00-04:00,VIVO,neutral
1314161.0,Meridian Bullish About Fiscal 2011 - Analyst Blog,2010-09-14 18:03:00-04:00,VIVO,neutral
1314162.0,Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2011 ,2010-09-13 09:46:00-04:00,VIVO,neutral
1314163.0,"Top 4 NASDAQ Stocks In The Healthcare Sector With The Highest Dividend Yield (CMED, VIVO, LNCR, ACET)",2010-08-04 06:41:00-04:00,VIVO,positive
1314164.0,William Blair & Co. Reiterates Market Perform on Meridian Bioscience (VIVO),2010-07-21 09:23:00-04:00,VIVO,neutral
1314165.0,Meridian Bioscience (VIVO) Sales Falls 11%,2010-07-20 09:27:00-04:00,VIVO,neutral
1314166.0,Jefferies Global Life Sciences Conference Takeaways; Diagnostics,2010-06-14 11:28:00-04:00,VIVO,neutral
1314167.0,William Blair & Company Maintains Meridian Bioscience (VIVO) Market Perform Rating,2010-03-18 11:43:00-04:00,VIVO,neutral
1314168.0,Hilliard Lyons Reiterates Long Term Buy Rating On VIVO,2009-11-12 17:32:00-05:00,VIVO,neutral
